All In Biotech

Drug Trial Radar · NCT06169527

A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

French Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

303

Actual

Start

Nov 28, 2023

Primary completion

Jul 5, 2028

Study completion Jul 5, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

    Dupilumab cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demographic characteristics of participants who receive dupilumab for ADTime frame: At baseline
  2. Weight characteristics of participants who receive dupilumab for ADTime frame: At baseline
  3. Height characteristics of participants who receive dupilumab for ADTime frame: At baseline
  4. Medical history characteristics of participants who receive dupilumab for ADTime frame: At baseline
  5. Comorbidities and treatments change from baselineTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  6. Atopic comorbidities and treatments change from baselineTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  7. Change from baseline in lifestyle habits of participants who receive dupilumab for ADTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
  8. Change from baseline in dupilumab doseTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  9. Change from baseline in dupilumab administrationTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  10. Change from baseline in dupilumab compliance with treatmentTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  11. Change from baseline in dupilumab temporary or permanent discontinuationTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  12. Change from baseline in dupilumab treatment switch to another therapyTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  13. Change from baseline in dupilumab treatment for concomitant AD treatmentsTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  14. Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)Time frame: At month 6, month 12, month 18, month 24, month 30, month 36
  15. Change in eczema severity using the Eczema Area and Severity Index (EASI)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  16. Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  17. Change in itch assessmentTime frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  18. Change in sleep disturbance NRSTime frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  19. Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  20. Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  21. Change in Dermatology Life Quality Index (DLQI)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  22. Change in Dermatitis Family Impact Questionnaire (DFI)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  23. Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
  24. Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)Time frame: At month 6, month 12, month 18, month 24, month 30, month 36
  25. Number of Adverse Events (AE)Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
  26. Change from baseline in Drug SurvivalTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number: 2500041

    Amiens, France

  • Investigational Site Number: 2500037

    Angers, France

  • Investigational Site Number: 2500021

    Argenteuil, France

  • Investigational Site Number: 2500044

    Armentières, France

  • Investigational Site Number: 2500018

    Arras, France

  • Investigational Site Number: 2500011

    Ars-Laquenexy, France

  • Investigational Site Number: 2500023

    Avignon, France

  • Investigational Site Number: 2500001

    Besançon, France

  • Investigational Site Number: 2500003

    Bron, France

  • Investigational Site Number: 2500043

    Caen, France

  • Investigational Site Number: 2500050

    Chambéry, France

  • Investigational Site Number: 2500006

    Clermont-Ferrand, France

  • Investigational Site Number: 2500005

    Dijon, France

  • Investigational Site Number: 2500004

    Epagny Metz Tessy, France

  • Investigational Site Number: 2500039

    Fort-de-France, France

  • Investigational Site Number: 2500045

    La Tronche, France

  • Investigational Site Number: 2500019

    Le Havre, France

  • Investigational Site Number: 2500040

    Le Mans, France

  • Investigational Site Number: 2500038

    Les Sables-d'Olonne, France

  • Investigational Site Number: 2500048

    Levallois-Perret, France

  • Investigational Site Number: 2500032

    Lille, France

  • Investigational Site Number: 2500002

    Limoges, France

  • Investigational Site Number: 2500036

    Lorient, France

  • Investigational Site Number: 2500029

    Marseille, France

  • Investigational Site Number: 2500028

    Montpellier, France

  • Investigational Site Number: 2500024

    Nantes, France

  • Investigational Site Number: 2500025

    Nice, France

  • Investigational Site Number: 2500020

    Nice, France

  • Investigational Site Number: 2500016

    Pau, France

  • Investigational Site Number: 2500009

    Périgueux, France

  • Investigational Site Number: 2500042

    Poitiers, France

  • Investigational Site Number: 2500022

    Pontoise, France

  • Investigational Site Number: 2500014

    Romans-sur-Isère, France

  • Investigational Site Number: 2500008

    Rouen, France

  • Investigational Site Number: 2500015

    Saint-Germain-en-Laye, France

  • Investigational Site Number: 2500027

    Saint-Mandé, France

  • Investigational Site Number: 2500026

    Saint-Nazaire, France

  • Investigational Site Number: 2500035

    Saint-Pierre, France

  • Investigational Site Number: 2500013

    Saint-Pierre, France

  • Investigational Site Number: 2500012

    Toulouse, France

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.